Yahoo · Oct 15, 2026
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?
Smart Beta ETF report for FTXH
FT
NASDAQ · FTXH
First Trust Nasdaq Pharmaceuticals ETF
Financial Services · Asset Management
$42.68
Up+$0.13 (+0.30%)
Updated Oct 26, 2026, 11:45 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 19.52M
- P/E ratio
- —
- Dividend yield
- 1.08%
- 52-week range
- $29.40 – $43.52
- Volume
- 83.51K
- Avg. volume
- 4.5K
Price performance · FTXH
FTXH price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
FTXH closed at $42.68 after 20 trading sessions, up 1.95% for the selected period.
- Last close
- $42.68
- Period change
- +1.95%
- Period low
- $40.43
- Period high
- $43.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $43.00 | $43.00 | $42.42 | $42.6751 | 83.51K |
| Oct 22, 2026 | $43.14 | $43.40 | $42.6727 | $43.1975 | 132.62K |
| Oct 21, 2026 | $42.49 | $42.80 | $42.41 | $42.75 | 52.06K |
| Oct 20, 2026 | $41.82 | $42.7408 | $41.82 | $42.7049 | 180.2K |
| Oct 19, 2026 | $41.52 | $41.892 | $41.52 | $41.5925 | 42.17K |
| Oct 16, 2026 | $42.17 | $42.17 | $41.59 | $41.6608 | 24.79K |
| Oct 15, 2026 | $41.80 | $42.46 | $41.80 | $41.97 | 60.62K |
| Oct 14, 2026 | $40.44 | $41.44 | $40.44 | $41.29 | 32.67K |
| Oct 13, 2026 | $41.31 | $41.31 | $40.395 | $40.43 | 28.47K |
| Oct 12, 2026 | $41.37 | $41.51 | $41.18 | $41.25 | 25.39K |
| Oct 9, 2026 | $40.60 | $41.37 | $40.60 | $41.27 | 1.26M |
| Oct 8, 2026 | $40.48 | $40.49 | $39.73 | $40.45 | 33.74K |
| Oct 7, 2026 | $40.26 | $41.125 | $40.26 | $40.675 | 84.78K |
| Oct 6, 2026 | $40.96 | $41.0601 | $40.08 | $40.4502 | 108.11K |
| Oct 5, 2026 | $40.57 | $40.9399 | $40.35 | $40.765 | 139.62K |
| Oct 2, 2026 | $40.82 | $40.8799 | $40.53 | $40.73 | 53.73K |
| Oct 1, 2026 | $41.32 | $41.485 | $40.80 | $40.82 | 103.64K |
| Sep 30, 2026 | $41.74 | $43.52 | $41.435 | $41.47 | 37.31K |
| Sep 29, 2026 | $41.79 | $42.09 | $41.325 | $41.77 | 37.22K |
| Sep 28, 2026 | $41.64 | $41.98 | $41.475 | $41.8569 | 76.49K |
Latest FTXH news
The latest Smart Investors Daily articles mentioning FTXH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
FTXH research
Overview
Company profile and research snapshot.
Company profile
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 2, 2026
Equity Outlook: AI, Higher Rates Raise The Bar For Diversification
Global equities advanced in the third quarter as market returns broadened away from technology. Read more here.
Yahoo · Sep 29, 2026
Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)?
Sector ETF report for FTXH
SeekingAlpha · Apr 3, 2026
Trump's 100% Pharma Tariffs Will Have A Limited Effect On The Sector
On Thursday, news broke that the US will likely start levying a 100% tariff on branded pharmaceutical imports. Read more here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
